ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2013
Relapse more common than reinfection in recurrent tuberculosis 1-2 years post treatment in urban Uganda.
Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- A systematic review of published literature describing factors associated with tuberculosis recurrence in people living with HIV in Africa.African health sciences · 2015Pooled it
- Short oral treatment regimens for rifampicin-resistant tuberculosis are safe and effective for young children: results from a field-based, non-randomised clinical trial from Kandahar, Afghanistan.The European respiratory journal · 2024Trial
- Factors Involved in Tuberculosis Recurrence in a Low-incidence Setting; Reactivation Predominates Over Reinfection in a 30-year Surveillance Study.Open forum infectious diseases · 2026Article
- Determinants of tuberculosis presentation and successful treatment outcome among tuberculosis patients in Geita, Tanzania.PloS one · 2026Article
- Endogenous reactivation cases identified by whole genome sequencing ofJournal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.American journal of respiratory and critical care medicine · 2024Article
- Relapse after treatment with standardized all-oral short regimens for rifampicin-resistant tuberculosis (RR-TB): A systematic review andJournal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- Antibiotic treatment modestly reduces protection againstInfection and immunity · 2024Article
- Antibiotic treatment modestly reduces protection against Mycobacterium tuberculosis reinfection in macaques.bioRxiv : the preprint server for biology · 2024Article
- Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-α agents: a nationwide population-based cohort study.Therapeutic advances in gastroenterology · 2024Article
- Unraveling tuberculosis patient cluster transmission chains: integrating WGS-based network with clinical and epidemiological insights.Frontiers in public health · 2024Article
- Advantages of analysing both pairwise SNV-distance and differing SNVs betweenMicrobial genomics · 2023Article
- Global Stability for an Endogenous-Reactivated Tuberculosis Model with Beddington-DeAngelis Incidence, Distributed Delay and Relapse.Qualitative theory of dynamical systems · 2023Article
- Recurrent tuberculosis in the Netherlands - a 24-year follow-up study, 1993 to 2016.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2022Article
- Molecular epidemiology of tuberculosis in the Somali region, eastern Ethiopia.Frontiers in medicine · 2022Article
- Microevolution of Mycobacterium tuberculosis Subpopulations and Heteroresistance in a Patient Receiving 27 Years of Tuberculosis Treatment in Germany.Antimicrobial agents and chemotherapy · 2021Article
- High Rates of Recurrent Tuberculosis Disease: A Population-level Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Relapse or Re-Infection, the Situation of Recurrent Tuberculosis in Eastern China.Frontiers in cellular and infection microbiology · 2021Article
- Review of tuberculosis treatment outcome reporting system in Denmark, a retrospective study cohort study from 2009 through 2014.BMC health services research · 2020Review
- Investigating Non-sterilizing Cure in TB Patients at the End of Successful Anti-TB Therapy.Frontiers in cellular and infection microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 2 countries.
Funding
Abstract
objectiveTo determine the proportion of recurrent tuberculosis (TB) due to relapse with the patient's initial strain or reinfection with a new strain of Mycobacterium tuberculosis 1-2 years after anti-tuberculosis treatment in Uganda, a sub-Saharan TB-endemic country.
designRecords of patients with culture-confirmed TB who completed treatment at an urban Ugandan clinic were reviewed. Restriction fragment length polymorphism (RFLP) patterns were used to determine relapse or reinfection. Associations between human immunodeficiency virus (HIV) positivity and type of TB recurrence were determined.
resultsOf 1701 patients cured of their initial TB episode with a median follow-up of 1.24 years, 171 (10%) had TB recurrence (8.4 per 100 person-years). Rate and risk factors for recurrence were similar to other studies from sub-Saharan Africa. Insertion sequence (IS) 6110-based RFLP of paired isolates from 98 recurrences identified 80 relapses and 18 reinfections. Relapses among HIV-positive and -negative patients were respectively 79% and 85% of recurrences.
conclusionsRelapse was more common and presented earlier than reinfection in both HIV-positive and -negative TB patients 1-2 years after completing treatment. These findings impact both the choice of retreatment drug regimen, as relapsing patients are at higher risk for acquired drug resistance, and clinical trials of new TB regimens with relapse as clinical endpoint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.